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ABSTRACT
Objective: We evaluated whether a short-term course with synbiotics may lower plasma p-Cresol
concentrations in kidney transplant patients (KTRs) who accumulate this uremic toxin both because of
increased production by their dysbiotic gut microbiome and because of reduced elimination by the
transplanted kidneys.
Methods: Thirty-six KTRs (29 males, mean age 49.6 § 9.1 years) with transplant vintage > 12 months,
stable graft function, and no episode of acute rejection or infection in the last 3 months were enrolled in
this single-center, parallel-group, double-blinded, randomized (2:1 synbiotic to placebo) study. Synbiotic
(Probinul Neutro, CadiGroup, Rome, Italy) or placebo was taken at home for 30 days, as 5 g powder
packets dissolved in water three times a day far from meals. The main outcome measure was the decrease
in total plasma p-Cresol measured by high-performance liquid chromatography at baseline and after 15
and 30 days of placebo or synbiotic treatment.
Results: After 15 and 30 days of treatment, plasma p-Cresol decreased by 40% and 33% from baseline
(both p < 0.05), respectively, in the synbiotic group, whereas it remained stable in the placebo group.
After 30 days of treatment, no signiﬁcant change was observed in either group in renal function, glycemia,
plasma lipids, or albumin concentration. Treatment was well tolerated and did not induce any change in
stool characteristics.
Conclusion: The results of this pilot study suggest that treatment with synbiotics may be effective to lower
plasma p-Cresol concentrations in KTRs. Prospective larger scale, longer term studies are needed to







p-Cresol is a prototypical uremic toxin whose levels are higher
in patients with chronic renal failure (CRF) than in normal
subjects both because of enhanced synthesis and of impaired
renal clearance [1–4]. Intestinal anaerobic bacteria through
phenylalanine and tyrosine oxidation synthesize this toxin [5],
which is then absorbed and metabolized into p-cresyl sulfate,
the main form of circulating p-Cresol in humans [6]. Because
of its prooxidant activity [7], p-Cresol exerts toxic effects on
endothelial cells [8,9], causing endothelial dysfunction [10–13].
Moreover, it damages kidney tubular cells [14,15] and pro-
motes tubule-interstitial ﬁbrosis [16,17]. These effects can
explain why high levels of p-Cresol predict a faster progression
of renal dysfunction and a higher cardiovascular morbidity and
mortality in patients with CRF [18]. It has therefore been sug-
gested that p-Cresol could represent a new cardiovascular risk
factor in CRF [11,18–21], and efforts are now directed to
develop new strategies to lower its plasma concentrations. It
has been recently shown that plasma p-Cresol concentrations
remain high after kidney transplantation especially in the pres-
ence of residual renal function impairment [22,23]. Evidence
also has been reported that it could worsen the cardiovascular
risk of renal transplant recipients (KTRs) who experience a
major cardiovascular event by 36 months after transplantation
high in about 40% of cases [22–27].
Because the dysbiotic gut microbiota of patients with CRF
and KTRs may produce p-Cresol in excess [22,23–28], thera-
peutic strategies normalizing the intestinal microﬂora should
decrease plasma p-Cresol levels in these patients. Such normali-
zation can be obtained by the administration of synbiotics; that
is, preformed combinations of probiotics—“live microorgan-
isms which, when administered in adequate amounts, confer a
health beneﬁt on the host”—and prebiotics—organic com-
pounds, usually oligosaccharides made up of 4 to 10 mono-
meric hexose units—that act as nutrients for probiotics [29].
Consistent with this hypothesis, a signiﬁcant decrease in total
plasma p-Cresol levels was obtained in patients with CRF after
a short-term treatment with a commercial preparation of
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synbiotics [30,31]. In the present study, we tested whether syn-
biotics may exert similar effects in KTRs.
Methods
Design
This was a single-center, parallel-group, 2:1 synbiotic to pla-
cebo randomized and double-blinded study. Uneven randomi-
zation was chosen to encourage patient participation [32]. The
study protocol was approved by the Ethical Committee of the
School of Medicine of the University Federico II of Naples and
all patients gave written informed consent. The study was car-
ried out in accordance with the WMA Helsinki Declaration as
revised in 1996.
Thirty-six KTRs (29 males and 7 female, mean age 49.6 §
9.1 years) in regular follow-up at the outpatient renal trans-
plantation clinic of the University Federico II of Naples were
enrolled in the study. Using a computer-generated random
binary list, they were allocated to one of 2 arms: synbiotic
(n D 24) and placebo (n D 12). Two patients in the synbiotic
group dropped out for reasons unrelated to treatment.
Inclusion criteria were as follows: age > 18 years, transplant
vintage > 12 months with stable graft function (serum creati-
nine < 2.5 mg/dl in the last 3 months), and no episode of acute
rejection or infection in the last 3 months. Patients with diar-
rhea, diabetes, malignancy, pregnancy, food intolerance, auto-
immune disorders, severe malnutrition, or clinical conditions
requiring artiﬁcial feeding were excluded from the study.
Study protocol
At the time of enrollment, anthropometric parameters were
assessed and body composition was determined with bioelectri-
cal impedance analysis as detailed elsewhere [33]. Dietary
intake, gastrointestinal symptoms, and stool characteristics
were also quantiﬁed as detailed below. Blood chemicals and
plasma p-Cresol concentration were measured as well. After
baseline evaluation, patients began their treatment at home
according to the schedule reported below. Blood samples for p-
Cresol determination and dietary and gastrointestinal symptom
assessment was performed after 15 and 30 days of treatment,
whereas blood chemicals and anthropometric parameters were
measured only at the end of the study, after 30 days of
treatment.
Treatment schedule
Synbiotic (Probinul Neutro, CadiGroup, Rome, Italy) or
placebo was taken at home for 30 days, as 5 g powder packets
to be dissolved in water three times a day far from meals. Each
Probinul Neutro packet contained lyophilized bacteria (5 £ 109
Lactobacillus plantarum, 2 £ 109 Lactobacillus casei subsp.
rhamnosus, 2 £ 109 Lactobacillus gasseri, 1 £ 109 Biﬁdobacte-
rium infantis, 1 £ 109 Biﬁdobacterium longum, 1 £ 109 Lacto-
bacillus acidophilus, 1 £ 109 Lactobacillus salivarius, 1 £ 109
Lactobacillus sporogenes, and 5 £ 109 Streptococcus thermophi-
lus), prebiotic inulin (2.2 g; VB Beneo Synergy 1, Beneo Iberica,
Barcelona, Spain) and 1.3 g of tapioca-resistant starch. Placebo
powder was comparable to the synbiotic in color, texture, and
taste and contained only cellulose. Both study groups remained
on a standard diet and drug regimen during the study.
Diet composition and dietary assessment
At the time of enrollment, patients were already taking the
standard diet that we recommend to all kidney transplant
recipients who attend our nutrition unit for consultation. This
Mediterranean pattern diet is based on foods rich in monoun-
saturated fatty acids, such as olive oil—the primary source of
fat in a Mediterranean diet—or in complex carbohydrates and
ﬁbers such as whole grains, fruit, vegetables, and legumes [34].
In accordance with current nutritional guidelines for kidney-
transplanted patients [35–37], our dietary plan ﬁts an energy
intake higher than 25/kcal/kg/ideal body weight/day, with 55%
of carbohydrates and total fat not exceeding 30% of calories
(fatty acids < 10% of calories and dietary cholesterol limited to
300 mg/day). In addition; protein intake is restricted to 0.8 g/kg
of ideal body weight/day. Our diet includes both insoluble and
soluble ﬁbers in a ratio of about 3 to 1 because of the high con-
tent of insoluble ﬁbers in whole grains and vegetables. Patients
are left free to drink water as they need and the average volume
of water intake ranges between 1.5 and 2.0 L/day.
Diet composition was determined by expert dietitians who
interviewed each patient using a detailed food frequency ques-
tionnaire that includes 130 foods and beverages [38]. This ques-
tionnaire inquires about amount and frequency of foods and
beverages consumed everyday by the patient. Data on nutrient
composition of the different foods were obtained using the
tables of the Italian National Institute of Nutrition, Souci’s
Food Composition and Nutrition Tables, and the European
Institute of Oncology as reported elsewhere [33,39]. Data were
analyzed with an Excel-based computer program.
Gastrointestinal symptom assessment
Gastrointestinal symptoms and stool characteristics were
quantiﬁed using a questionnaire similar to that described by
Nakabayashi et al. [30] and Guida et al. [31]. More speciﬁcally,
upper and inferior abdominal pain, borborygm, and ﬂatus were
scored as frequent ( D 1), occasional ( D 2), or almost absent
( D 3), whereas ease of defecation was scored as difﬁcult ( D 1),
easy ( D 2), or very easy ( D 3). Defecation frequency was
scored as follows: 1 D once every 3 days; 2 D once every 2 days;
3 D once/day; 4 D >twice/day. Stool shape was recorded
according to the Bristol stool scale [30].
Analytical determinations
Blood chemicals were assayed by standard analytical methods in
venous blood samples. Speciﬁcally, serum albumin was deter-
mined by nephelometry, whereas plasma lipids were measured
with Architect i2000SR (Abbott Park, IL). Estimated glomerular
ﬁltration rate (eGFR) was evaluated by the modiﬁcation of diet
in renal disease formula. Total p-Cresol was measured by high-
performance liquid chromatography after heat–acid denaturation
and ethyl acetate extraction [40]. Because acidiﬁcation released
p-Cresol conjugates from plasma proteins and converted p-cresyl































sulfate and p-cresyl glucuronide into p-Cresol, this method mea-
sured total plasma p-Cresol concentration that is mainly contrib-
uted by p-cresyl sulfate [41].
Statistical analysis
Data were assayed for normality distribution with the Shapiro-
Wilk test and reported as means § SD if normally distributed
and as medians (25th–75th percentiles) if not. p-Cresol concen-
trations were log-transformed before analysis. Student’s t test
and Mann-Whitney U test were used for 2-group statistical
comparisons of normally and nonnormally distributed data,
respectively. Time-dependent changes in normally distributed
data were analyzed by 2-way repeated measures analysis of var-
iance using the time of evaluation and placebo or synbiotic
treatment as within-subject and between-subject factors,
respectively. Mann-Whitney U test was used to compare gas-
trointestinal symptom scores in synbiotic and placebo groups
at each time point. Conversely, time-dependent changes in
these variables in each of these 2 groups were evaluated with
Kruskall-Wallis nonparametric one-way analysis of variance.
The threshold for statistical signiﬁcance was p < 0.05. Data
were analyzed using SPSS 20.0 (SPSS Inc., Chicago, IL).
Results
As shown in Table 1, there was no signiﬁcant difference
between synbiotic and placebo groups in demographic, anthro-
pometric, and biochemical variables or body composition. The
majority of our patients were in CRF stage II/III (20/22 in the
synbiotic group and 8/12 in the placebo group), whereas only a
few were in stage IV (2 in the synbiotic group and 4 in the pla-
cebo group). Renal function, lipid proﬁle, and plasma concen-
tration of albumin and glucose remained stable during the
study in both groups and were not affected by treatment
(Table 2). In patients taking the synbiotic, p-Cresol concentra-
tion was lower than baseline after 15 and 30 days of treatment
(¡40% and ¡33% vs basal, respectively, both p < 0.05),
whereas it remained stable in the placebo group (¡25% and
¡10% vs basal, respectively, ns; Fig. 1). No change was
observed in energy or nutrient intake with the only exception
of a marginal decrease in lipid intake after 15 days of follow-up
in the placebo group (Table 3). Notably, there was no change in
the ingested amount of phenylalanine and tyrosine, the main
source for p-Cresol synthesis by intestinal bacteria [5] (Table 3).
Because of the high ﬁber content of Probinul Neutro, ﬁber
intake increased, whereas the protein–ﬁber ratio decreased dur-
ing treatment in patients in the synbiotic group. Treatment
with synbiotics was well tolerated with no relevant gastrointes-
tinal adverse effect; borborygmi were reported as occasional by
most patients (60%), whereas abdominal pain was virtually
absent in both groups.
Discussion
This pilot study provides preliminary evidence that a short-
course treatment with an oral synbiotic signiﬁcantly lowers
plasma p-Cresol levels in KTRs.
The most likely explanation for our ﬁndings is that synbiot-
ics modiﬁed the composition of the dysbiotic gut microbiota
that produces p-Cresol in excess in KTRs [42–44]. Although
we did not perform a metagenomic study, evidence has been
reported that the probiotic microorganisms contained in synbi-
otic colonize the gut of patients affected with CRF and replace
the preexisting pathologic ﬂora [45]. Upon gut colonization by
these beneﬁcial microrganisms, a marked decrease in p-Cresol
generation in the gut is expected to occur. Indeed, these micro-
organisms belong to species such as Lactobacillus that do not
express the enzymes required to convert aromatic amino acids
in this uremic toxin. In addition, the probiotic microorganisms
Lactobacillus and Biﬁdobacterium sp. produce lactic acid and
short-chain fatty acids that lower the pH of gut lumen, setting
up unfavorable conditions for the growth of p-Cresol-produc-
ing harmful bacteria such as Clostridium difﬁcilis [46].
Because of the high ﬁber content of the synbiotic prepara-
tion, another factor that could have played a role in lowering p-
Table 2. Biochemical parameters in the synbiotic (n.22) and placebo (n.12) groups
at baseline and at the end of the study.
Baseline T30
Total Cholesterol (mg/dL) Synbiotic 184.4 § 34.3 191.1§37.8
Placebo 191.0 § 22.9 195.8 § 19.1
HDL-Cholesterol (mg/dL) Synbiotic 62.7 § 21.1 59.4§ 20.1
Placebo 65.3 § 13.9 70.3§ 17.6
Triglycerides (mg/dL) Synbiotic 91 (83.0 – 136.0) 132.0 (77.0 – 209.0)
Placebo 151.5 (130.0 – 163.0) 148.5 (141.0 – 157.0)
Glucose (mg/dL) Synbiotic 77.0 (69.0 – 83.0) 81.0 (73.0 – 89.0)
Placebo 76.0 (64.0 – 99.0) 75.0 (64.0 – 102.0)
Albumin (mg/dL) Synbiotic 4.53 § 0.3 4.35§ 0.3
Placebo 4.60 § 0.4 4.60§ 0.2
eGFR (ml/min) Synbiotic 50.6 § 17.6 53.5§ 16.0
Placebo 58.5 § 24.0 57.3§ 22.1
Data are expressed as means § SD or median and interquartile range, as
appropriate.
Table 1. Baseline characteristics of the study population.a
Synbiotic Placebo
n 22 12
Sex (male/female) 16/6 12/0
Age (years) 54.0 § 8.9 47.3 § 8.5
eGFR (ml/min) 50.6 § 17.6 58.5 § 24.0
Body weight (kg) 71.7 § 10.8 79.6 § 4.3*
Heigth (cm) 168.0 § 0.1 176 § 0.04*
BMI (kg/m2) 25.6 § 1.5 25.2 § 3.4
Waist circumference (cm) 87.7 § 12.8 101.8 § 4.9
TBW, % BW 58.0 § 3.2 59.6 § 5.8
ECW, % TBW 45.2 § 2.6 47.1 § 4.9
FM, % BW 23.1 § 4.8 19.3 § 7.6
FFM, % BW 76.9 § 4.8 80.7 § 7.9
Immunosuppressive drug treatment
Corticosteroids (%) 83 91
Cyclosporin (%) 67 73
Tacrolimus (%) 33 9
Mycophenolic acid (%) 83 36




eGFR D estimated glomerular ﬁltration rate, BMI D body mass index, TBW D total
body water, BW D body weight, ECWD extracellular water, FM D fat mass,
FFM D fat-free mass, CKDD chronic kidney disease.
aData are expressed as means§ SD.
p < 0.05.































Cresol is the increase in ﬁber intake. Indeed, in our patients, we
observed a signiﬁcant decrease in the ratio between protein and
ﬁber intake, an index that has a strong positive correlation with
p-Cresol plasma levels [47] and cardiovascular risk in CRF [48].
If conﬁrmed in larger studies, our evidence that synbiotics
lower p-Cresol plasma levels in KTRs could have relevant
implications for the treatment of these patients. It is well
known, indeed, that cardiovascular risk remains high even if
kidney transplantation is fully successful [24,25,27], and evi-
dence suggests that this can be due in part to the accumula-
tion of p-Cresol [23]. An important argument to suggest the
use of synbiotics in KTRs as a tool to lower plasma p-Cresol
is that they were very well tolerated. This is an important
advantage in comparison with other nutritional approaches
that have been proposed to lower p-Cresol in CRF, such as
diet supplements with pea hull and inulin that cause a signiﬁ-
cant increase in stool frequency [49]. It is also worth noting
that by normalizing gut dysbiotic microbiota, synbiotics could
also decrease the occurrence of serious gastrointestinal com-
plications such as the severe diarrhea caused by Clostridium
difﬁcilis [50–52]. Treatment with the synbiotic did not induce
major changes in any of the metabolic parameters that were
evaluated, although a nonsigniﬁcant trend for an increase in
tryglicerides was observed. Remarkably, changes in plasma
lipids upon synbiotic treatment have been reported already in
previous studies with conﬂicting results [53].
Figure 1. Box plot of p-Cresol plasma concentrations in the symbiotic (n D 22) and placebo (n D 12) groups at different times of the study. p < 0.01 vs baseline.
yp < 0.01 vs placebo.
Table 3. Time-dependent changes in BMI and daily energy and nutrient intake in patients belonging to the synbiotic (n D 22) and placebo (n D 12) groups.
Baseline 15th Day 30th Day
BMI (kg/m2) Synbiotic 25.2§ 3.4 25.2 § 3.5 25.2§ 3.4
Placebo 25.6 § 1.5 25.3 § 1.4 25.4§ 1.3
Body weight (kg) Synbiotic 71.7 § 10.8y 71.8 § 11.2y 71.8§ 10.8y
Placebo 79.6 § 4.3 78.7 § 4.6 78.8§ 4.5
Waist circumference (cm) Synbiotic 87.7 § 12.3y 92.4 § 13.7 92.7§ 6.9
Placebo 101.5 § 4.5 100.8 § 3.6 99.2§ 2.7
Energy (kcal/day) Synbiotic 2589.0 § 496.0 2360.0 § 373.0 2274.0 § 482.0
Placebo 2308.0 § 108.0 2777.0 § 477.0* 2488.0 § 402.0
Energy/ideal body weight (kcal/kg) Synbiotic 38.9 § 4.7 35.9 § 4.0 34.4§ 5.5
Placebo 31.9 § 1.6 38.5 § 7.4 34.5§ 6.1
Lipid (% energy) Synbiotic 28.0 § 3.9 27.2 § 2.9 27.1§ 3.2
Placebo 31.3 § 2.9 26.7 § 4.6* 27.8§ 3.3
Carbohydrates (% energy) Synbiotic 54.2 § 4.3 55.6 § 4.1 55.0§ 4.7
Placebo 52.6 § 2.8 56.1 § 5.5 55.8§ 3.3
Protein (% energy) Synbiotic 16.4 § 2.6 16.4 § 3.1 16.7§ 2.6
Placebo 14.9 § 1.3 15.1 § 2.7 14.4§ 1.1
Protein (g/day) Synbiotic 106.2 § 28.3 96.7 § 24.3 94.4§ 23.8
Placebo 85.8 § 8.5 102.5 § 8.6 90.6§ 16.4
Phenylalanine (g/day) Synbiotic 4.0 § 0.1 3.4 § 0.1 3.4 § 1.0
Placebo 3.2 § 0.5 4.0 § 0.4 3.4 § 0.8
Tyrosine (g/day) Synbiotic 2.9 § 1.0 2.4 § 0.8 2.4 § 0.7
Placebo 2.3 § 0.4 2.7 § 0.4 2.4 § 0.5
Fiber (g/day)a Synbiotic 22.8 § 7.8y 32.6 § 4.6*y 30.6§ 4.2*y
Placebo 16.6 § 3.3 21.9 § 6.3 18.1§ 7.0
Protein/ﬁber ratioa Synbiotic 4.8 § 1.2 3.0 § 0.8*y 3.1 § 0.7*y
Placebo 5.4 § 1.3 5.0 § 1.4 5.5 § 1.7
BMI D body mass index.
aAlso including the ﬁber content of the synbiotic preparation.
p < 0.01 vs baseline.
yp < 0.01 vs placebo.































This was a small-scale pilot study, and its ﬁndings will have to
be conﬁrmed in a larger number of patients. Because p-Cresol
accumulation in KTRs parallels the severity of renal failure
[22], an important issue that will have to be addressed by future
investigations is whether synbiotics are similarly effective in
patients with different degrees of renal function impairment.
Indeed, the majority of our patients were in stage II/III CRF,
with only few in stage IV and, because of the small size of our
sample, we did not perform any patient stratiﬁcation according
to CRF stage. Another important point that remains to be clari-
ﬁed is whether synbiotic treatment does really impact the car-
diovascular prognosis of KTRs. Indeed, because of the very
short duration of our pilot study, we did not assess any surro-
gate or clinically relevant endpoint.
In conclusion, we showed that a short-course treatment with
a symbiotic preparation given daily by mouth signiﬁcantly
reduced circulating p-Cresol plasma concentration in kidney
transplant patients. Because of the evidence suggesting a close
link between cardiovascular risk and p-Cresol in these patients,
our results prompt further prospective studies to explore
whether lowering the circulating concentrations of this uremic
toxin synbiotics could also improve the cardiovascular progno-
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